Skip to main content

Advertisement

SpringerLink
Log in

Microalbuminuria in type 1 and type 2 diabetes mellitus: Evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

A cumulative incidence of diabetic nephropathy of 25% to 40% has been documented after duration of diabetes of at least 25 years in both type 1 and type 2 diabetic patients. Diabetic nephropathy has become the leading cause (25%-44%) of end-stage renal failure in Europe, the United States, and Japan. Until the early 1980s, no renoprotective treatment was available for use in diabetic nephropathy. Death occurred on average 5 to 7 years after the onset of persistent proteinuria. The two main treatment strategies for prevention of diabetic nephropathy are improved glycemic control and blood pressure lowering, particularly using drugs blocking the reninangiotensin system. Megatrials and meta-analyses have clearly demonstrated the beneficial effect of both the above-mentioned treatment modalities. Secondary prevention, that is, treatment modalities applied to diabetic patients at high risk for developing diabetic nephropathy (eg, those with microalbuminuria) has been documented, applying angiotensin converting enzyme inhibitors and angiotensin II receptor blockade. The renoprotective effects of these drugs are independent of their beneficial reduction in blood pressure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Parving H-H, Østerby R, Ritz E: Diabetic nephropathy. In The Kidney, edn 6. Edited by Brenner BM. Philadelphia: WB Saunders; 2000:1731–1773.

    Google Scholar 

  2. Viberti GC, Mogensen CE, Groop L, Pauls JF, the European Microalbuminuria Captopril Study Group: Effect of Captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 1994, 271:275–279.

    Article  PubMed  CAS  Google Scholar 

  3. Laffel LM, McGill JB, Gans DJ: The beneficial effect of angiotensin- converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Am J Med 1995, 99:497–504.

    Article  PubMed  CAS  Google Scholar 

  4. O’Donnell MJ, Rowe BR, Lawson N, et al.: Placebo-controlled trial of lisinopril in normotensive diabetic patients with incipient nephropathy. J Hum Hypertens 1993, 7:327–332.

    PubMed  CAS  Google Scholar 

  5. Crepaldi G, Carta Q, Deferrari G, et al.: Effects of lisinopril and nifedipine on the progression of overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. Diabetes Care 1998, 21:104–110.

    Article  PubMed  CAS  Google Scholar 

  6. The EUCLID Study Group: Randomised placebo-controlled trial of lisinopril in normotensive patients with insulindependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997, 349:1787–1792.

    Article  Google Scholar 

  7. Mathiesen ER, Hommel E, Giese J, Parving H-H: Efficacy of captopril in postponing nephropathy in normotensive diabetic patients with microalbuminuria. Br Med J 1991, 303:81–87.

    CAS  Google Scholar 

  8. Marre M, Chatellier G, Leblanc H, et al.: Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. Br Med J 1988, 297:1092–1095.

    CAS  Google Scholar 

  9. Melbourne Diabetic Nephropathy Study Group: Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. Br Med J 1991, 302:210–216.

    Article  Google Scholar 

  10. Ebbehoj E, Poulsen PL, Nosadini R: Early ACE-i intervention in microalbuminuria:24h BP, renal function, and exercise changes [abstract]. Diabetologia 1998, 41:A5.

    Google Scholar 

  11. Barnes LA, Bilous RW, Tate H, Remuzzi G: The effect of three years of antihypertensive therapy in renal structure in type 1 diabetic patients with albuminuria. Diabetologia 2001, 50:843–850.

    Google Scholar 

  12. Bojestig M, Karlberg BE, Lindstrom T, Nystrom FH: Reduction of ACE activity is insufficient to decrease microalbuminuria in normotensive patients with type 1 diabetes. Diabetes Care 2001, 24:919–924.

    Article  PubMed  CAS  Google Scholar 

  13. The ATLANTIS Study Group: Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients wihout hypertension. Diabetes Care 2000, 23:1823–1829.

    Article  Google Scholar 

  14. The ACE Inhibitors in Diabetic Nephropathy Trialist Group: Should all type 1 diabetic microalbuminuric patients receive ACE inhibitors? A meta-regression analysis. Ann Intern Med 2001, 134:370–379. This meta-analysis includes all 12 studies dealing with the effect of ACE inhibitors in normotensive, microalbuminuric type 1 diabetic patients.

    Google Scholar 

  15. Mathiesen ER, Hommel E, Hansen HP, et al.: Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. Br Med J 1999, 319:24–25.

    CAS  Google Scholar 

  16. Mogensen CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes. N Engl J Med 1984, 310:356–360.

    Article  PubMed  CAS  Google Scholar 

  17. Ravid M, Savin H, Jutrin I, et al.: Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993, 118:577–581.

    PubMed  CAS  Google Scholar 

  18. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355:253–259. This substudy deals with the beneficial effect of ACE inhibitors on vascular endpoints in diabetic patients in the HOPE study.

    Article  Google Scholar 

  19. Lacourciere Y, Nadeau A, Poirier L, Tancrede G: Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis. Hypertension 1993, 21:786–794.

    PubMed  CAS  Google Scholar 

  20. Lebovitz HE, Wiegmann TB, Cnaan A, et al.: Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int Suppl 1994, 45(Suppl 45):S150-S155.

    PubMed  CAS  Google Scholar 

  21. Trevisan R, Tiengo A: Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive noninsulin- dependent diabetic patients. North-East Italy Microalbuminuria Study Group. Am J Hypertens 1995, 8:876–883.

    Article  PubMed  CAS  Google Scholar 

  22. Agardh C-D, Garcia-Puig J, Charbonnel B, et al.: Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens 1996, 10:185–192.

    PubMed  CAS  Google Scholar 

  23. Chan JC, Ko GT, Leung DH, et al.: Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 2000, 57:590–600.

    Article  PubMed  CAS  Google Scholar 

  24. Tatti P, Pahor M, Byington RP, et al.: Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998, 21:597–603.

    Article  PubMed  CAS  Google Scholar 

  25. UK Prospective Diabetes Study (UKPDS) Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. Br Med J 1998, 317:713–720. This substudy indicates a similar beneficial effect on vascular endpoints of ACE inhibitors versus ß-blockers in hypertensive type 2 diabetic patients.

    Google Scholar 

  26. Estacio RO, Jeffers BW, Gifford N, Schrier RW: Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000, 23:B54-B64.

    PubMed  Google Scholar 

  27. Parving H-H, Lehnert H, Bröchner-Mortensen J, et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870–878. This study demonstrates that an angiotensin II receptor blocker has a renoprotective effect above and beyond its beneficial impact on blood pressure.

    Article  PubMed  CAS  Google Scholar 

  28. Mogensen CE, Neldam S, Tikkanen I, et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study [in process citation]. Br Med J 2000, 321:1440–1444.

    Article  CAS  Google Scholar 

  29. Gaede P, Vedel P, Parving H-H, Pedersen O: Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999, 353:617–622.

    Article  PubMed  CAS  Google Scholar 

  30. Mogensen CE, Keane WF, Bennett PH, et al.: Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995, 346:1080–1084.

    Article  PubMed  CAS  Google Scholar 

  31. American Diabetes Association: Diabetic nephropathy. Diabetes Care 2002, 25:585–589.

    Article  Google Scholar 

  32. Parving H-H: Initiation and progression of diabetic nephropathy. N Engl J Med 1996, 335:1682–1683.

    Article  PubMed  CAS  Google Scholar 

  33. Nelson RG, Bennett PH, Beck GJ, et al.: Development and progression of renal disease in Pima indians with noninsulin- dependent diabetes mellitus. N Engl J Med 1996, 335:1636–1642.

    Article  PubMed  CAS  Google Scholar 

  34. Ravid M, Lang R, Rachmani R, Lishner M: Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. Arch Intern Med 1996, 156:286–289.

    Article  PubMed  CAS  Google Scholar 

  35. Ahmad J, Siddiqui MA, Ahmad H: Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 1997, 20:1576–1581.

    Article  PubMed  CAS  Google Scholar 

  36. Parving HH: Diabetic nephropathy: prevention and treatment. Kidney Int 2001, 60:2041–2055.

    Article  PubMed  CAS  Google Scholar 

  37. Jarrett RJ, Viberti GC, Argyropoulos A, et al.: Microalbuminuria predicts mortality in non-insulin-dependent diabetes. Diabetic Med 1984, 1:17–19.

    Article  PubMed  CAS  Google Scholar 

  38. Mattock MB, Morrish NJ, Viberti GC, et al.: Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes 1992, 41:736–741.

    Article  PubMed  CAS  Google Scholar 

  39. MacLeod JM, Lutale J, Marshall SM: Excess mortality in type 2 diabetic patients with minimal elevation of albumin excretion. Diabetologia 1992, 35(Suppl 1):A34.

    Google Scholar 

  40. Atkinson AB, Beatty OL, Ritchie CM, et al.: Clinic urinary albumin concentration predicts both mortality and progression to nephropathy in NIDDM: results of an 8 year prospective study. Diabetic Med 1993, 10(Suppl 1):S4.

    Google Scholar 

  41. Gall M-A, Borch-Johnsen K, Nielsen FS, et al.: Micro- and macroalbuminuria as predictors of mortality in non-insulindependent diabetes. Diabetologia 1993, 36(Suppl 1):A207.

    Google Scholar 

  42. Stiegler H, Sandl E, Schulz K, et al.: Morbidity, mortality, and albuminuria in type 2 diabetic patients: a three-year prospective study of a random cohort in general practice. Diabetic Med 1992, 9:646–653.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Steno Diabetes Center, Niels Steensens Vej 2, DK-2820, Gentofte, Denmark

    Hans-Henrik Parving DMSc & Peter Hovind MD

Authors
  1. Hans-Henrik Parving DMSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Hovind MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Parving, HH., Hovind, P. Microalbuminuria in type 1 and type 2 diabetes mellitus: Evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy. Current Science Inc 4, 387–393 (2002). https://doi.org/10.1007/s11906-002-0069-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-002-0069-3

Keywords

Search

Navigation